Literature DB >> 14519637

The impact of p53 protein core domain structural alteration on ovarian cancer survival.

Stephen L Rose1, Andrew D Robertson, Michael J Goodheart, Brian J Smith, Barry R DeYoung, Richard E Buller.   

Abstract

PURPOSE: Although survival with a p53 missense mutation is highly variable, p53-null mutation is an independent adverse prognostic factor for advanced stage ovarian cancer. By evaluating ovarian cancer survival based upon a structure function analysis of the p53 protein, we tested the hypothesis that not all missense mutations are equivalent. EXPERIMENTAL
DESIGN: The p53 gene was sequenced from 267 consecutive ovarian cancers. The effect of individual missense mutations on p53 structure was analyzed using the International Agency for Research on Cancer p53 Mutational Database, which specifies the effects of p53 mutations on p53 core domain structure. Mutations in the p53 core domain were classified as either explained or not explained in structural or functional terms by their predicted effects on protein folding, protein-DNA contacts, or mutation in highly conserved residues. Null mutations were classified by their mechanism of origin.
RESULTS: Mutations were sequenced from 125 tumors. Effects of 62 of the 82 missense mutations (76%) could be explained by alterations in the p53 protein. Twenty-three (28%) of the explained mutations occurred in highly conserved regions of the p53 core protein. Twenty-two nonsense point mutations and 21 frameshift null mutations were sequenced. Survival was independent of missense mutation type and mechanism of null mutation.
CONCLUSIONS: The hypothesis that not all missense mutations are equivalent is, therefore, rejected. Furthermore, p53 core domain structural alteration secondary to missense point mutation is not functionally equivalent to a p53-null mutation. The poor prognosis associated with p53-null mutation is independent of the mutation mechanism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14519637

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  5 in total

1.  MET-dependent cancer invasion may be preprogrammed by early alterations of p53-regulated feedforward loop and triggered by stromal cell-derived HGF.

Authors:  Chang-Il Hwang; Jinhyang Choi; Zongxiang Zhou; Andrea Flesken-Nikitin; Alexander Tarakhovsky; Alexander Yu Nikitin
Journal:  Cell Cycle       Date:  2011-11-15       Impact factor: 4.534

2.  Disruptive TP53 mutation is associated with aggressive disease characteristics in an orthotopic murine model of oral tongue cancer.

Authors:  Daisuke Sano; Tong-Xin Xie; Thomas J Ow; Mei Zhao; Curtis R Pickering; Ge Zhou; Vlad C Sandulache; David A Wheeler; Richard A Gibbs; Carlos Caulin; Jeffrey N Myers
Journal:  Clin Cancer Res       Date:  2011-09-08       Impact factor: 12.531

Review 3.  Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis.

Authors:  Sabita N Saldanha; Trygve O Tollefsbol
Journal:  J Cell Physiol       Date:  2014-04       Impact factor: 6.384

4.  Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study.

Authors:  Ken H Young; Karen Leroy; Michael B Møller; Gisele W B Colleoni; Margarita Sánchez-Beato; Fábio R Kerbauy; Corinne Haioun; Jens C Eickhoff; Allen H Young; Philippe Gaulard; Miguel A Piris; Terry D Oberley; William M Rehrauer; Brad S Kahl; James S Malter; Elias Campo; Jan Delabie; Randy D Gascoyne; Andreas Rosenwald; Lisa Rimsza; James Huang; Rita M Braziel; Elaine S Jaffe; Wyndham H Wilson; Louis M Staudt; Julie M Vose; Wing C Chan; Dennis D Weisenburger; Timothy C Greiner
Journal:  Blood       Date:  2008-06-17       Impact factor: 22.113

5.  Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies.

Authors:  Cécile Le Page; David G Huntsman; Diane M Provencher; Anne-Marie Mes-Masson
Journal:  Cancers (Basel)       Date:  2010-05-26       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.